All Stories

  1. Targeting Tumor-Draining Lymph Nodes to Improve the Therapeutic Potential of Oncolytic Viruses

    Article • Cancer Immunology Research, January 2026, American Association for Cancer Research (AACR)

    howard kaufman

  2. Promoting the therapeutic potential of interleukin-7 (IL-7) by expression in viral vectors

    Article • Cancer Gene Therapy, September 2025, Springer Science + Business Media

    howard kaufman

  3. Data from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors

    Article • July 2025, American Association for Cancer Research (AACR)

    howard kaufman

  4. Figures raw data & plotting code from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors

    Article • July 2025, American Association for Cancer Research (AACR)

    howard kaufman

  5. Supplementary Table S1 from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors

    Article • July 2025, American Association for Cancer Research (AACR)

    howard kaufman

  6. Supplementary Table S2 from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors

    Article • July 2025, American Association for Cancer Research (AACR)

    howard kaufman

  7. Supplementary Table S3 from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors

    Article • July 2025, American Association for Cancer Research (AACR)

    howard kaufman

  8. Supplementary Table S4 from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors

    Article • July 2025, American Association for Cancer Research (AACR)

    howard kaufman

  9. A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors

    Article • Molecular Cancer Therapeutics, March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  10. Data from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  11. Supplementary Data from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  12. Supplementary Figure S1 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  13. Supplementary Figure S2 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  14. Supplementary Figure S3 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  15. Supplementary Figure S4 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  16. Supplementary Figure S5 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  17. Supplementary Figure S6 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  18. Supplementary Figure S7 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  19. Supplementary Figure S8 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  20. Supplementary Figure S9 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  21. Supplementary Table S1 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  22. Supplementary Table S2 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  23. Supplementary Table S3 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  24. Supplementary Table S4 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  25. Supplementary Table S5 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • March 2025, American Association for Cancer Research (AACR)

    howard kaufman

  26. Using oncolytic viruses to induce hyperacute rejection against cancer

    Article • Nature Reviews Clinical Oncology, February 2025, Springer Science + Business Media

    howard kaufman

  27. The Evolving Role of ctDNA in Merkel Cell Carcinoma: Challenges and Opportunities

    Article • Journal of Cutaneous Oncology, January 2025, Society of Cutaneous Oncology

    howard kaufman

  28. Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma

    Article • Molecular Cancer Therapeutics, December 2024, American Association for Cancer Research (AACR)

    howard kaufman

  29. Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial

    Article • Nature Communications, August 2024, Springer Science + Business Media

    howard kaufman

  30. Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?

    Article • Journal for ImmunoTherapy of Cancer, May 2024, BMJ

    howard kaufman

  31. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival

    Article • Journal for ImmunoTherapy of Cancer, April 2024, BMJ

    Hiroaki Wakimoto, howard kaufman

  32. A Closer Look: Evaluating Mohs Surgery's Role in the Treatment of Invasive Melanoma of the Head and Neck

    Article • Journal of Cutaneous Oncology, January 2024, Society of Cutaneous Oncology

    howard kaufman

  33. Perspectives on Medical Aid in Dying: A Multifaceted Ethical Discussion

    Article • Journal of Cutaneous Oncology, January 2024, Society of Cutaneous Oncology

    howard kaufman

  34. To Screen or Not To Screen, That is the Question

    Article • Journal of Cutaneous Oncology, July 2023, Society of Cutaneous Oncology

    howard kaufman

  35. Perioperative Immunotherapy for High-Risk Resectable Melanoma - A New Standard?

    Article • Journal of Cutaneous Oncology, January 2023, Society of Cutaneous Oncology

    howard kaufman

  36. Skin Cancer Chemoprevention for Solid Organ Transplant Recipients - The Search Continues

    Article • Journal of Cutaneous Oncology, January 2023, Society of Cutaneous Oncology

    howard kaufman

  37. Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma: Ready for Prime Time?

    Article • Journal of Cutaneous Oncology, January 2023, Society of Cutaneous Oncology

    howard kaufman

  38. Neoadjuvant Nivo/Rela for Resectable Melanoma

    Article • Journal of Cutaneous Oncology, January 2022, Society of Cutaneous Oncology

    howard kaufman

  39. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions

    Article • American Journal of Clinical Dermatology, August 2020, Springer Science + Business Media

    howard kaufman

  40. Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma

    Article • OncoImmunology, April 2019, Taylor & Francis

    Samuel Rabkin, howard kaufman

  41. Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

    Article • OncoImmunology, February 2019, Taylor & Francis

    Samuel Rabkin, howard kaufman

  42. Two roads for oncolytic immunotherapy development

    Article • Journal for ImmunoTherapy of Cancer, February 2019, BMJ

    howard kaufman

  43. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis

    Article • Journal of Cancer Research and Clinical Oncology, August 2018, Springer Science + Business Media

    howard kaufman

  44. Finding gold in tumour immunotherapy

    Article • The Lancet Oncology, October 2017, Elsevier

    howard kaufman

  45. Interleukin-12

    Article • January 2016, Springer Science + Business Media

    howard kaufman

  46. Melanoma

    Article • January 2016, Springer Science + Business Media

    howard kaufman

  47. Surgical Management of Melanoma

    Article • November 2015, Springer Science + Business Media

    howard kaufman

  48. Combination Immunotherapy for Melanoma

    Article • JAMA Oncology, June 2015, American Medical Association (AMA)

    howard kaufman

  49. Introduction on Cancer Immunology and Immunotherapy

    Article • August 2014, Springer Science + Business Media

    howard kaufman

  50. Melanoma as a model for precision medicine in oncology

    Article • The Lancet Oncology, March 2014, Elsevier

    howard kaufman

  51. Modified Oncolytic Herpesviruses for Gene Therapy of Cancer

    Article • January 2014, Elsevier

    howard kaufman

  52. The Use of Oncolytic Herpesvirus for the Treatment of Cancer

    Article • January 2014, Springer Science + Business Media

    howard kaufman

  53. CTLA-4

    Article • January 2013, Springer Science + Business Media

    howard kaufman

  54. Interleukin 2

    Article • January 2013, Springer Science + Business Media

    howard kaufman

  55. Cytokines in the Treatment of Cancer

    Article • September 2012, Springer Science + Business Media

    Dr Howard L Kaufman, howard kaufman

  56. Vaccines for Melanoma and Renal Cell Carcinoma

    Article • Seminars in Oncology, June 2012, Elsevier

    howard kaufman

  57. Modulating the Tumor Microenvironment

    Article • November 2011, Springer Science + Business Media

    Dr Howard L Kaufman, howard kaufman

  58. An update on TroVax® for the treatment of progressive castration-resistant prostate cancer

    Article • OncoTargets and Therapy, May 2011, Taylor & Francis

    Dr Howard L Kaufman, howard kaufman

  59. Gene Therapy for Antitumor Vaccination

    Article • January 2009, Springer Science + Business Media

    howard kaufman

  60. Molecular Targeting in Oncology

    Article • January 2008, Springer Science + Business Media

    Dr Howard L Kaufman, howard kaufman

  61. In Reply

    Article • Journal of Clinical Oncology, July 2006, American Society of Clinical Oncology (ASCO)

    howard kaufman

  62. DNA Vaccines for Cancer Immunotherapy

    Article • January 2006, Springer Science + Business Media

    Dr Howard L Kaufman, howard kaufman

  63. Pox Viral Vaccine Approaches

    Article • Seminars in Oncology, December 2005, Elsevier

    howard kaufman

  64. Columbia University

    Article • The Lancet Oncology, October 2005, Elsevier

    Dr Howard L Kaufman, howard kaufman

  65. Immunotherapy for melanoma

    Article • Clinics in Dermatology, May 2004, Elsevier

    howard kaufman

  66. Surgical treatment of stage IV melanoma

    Article • Clinics in Dermatology, May 2004, Elsevier

    howard kaufman

  67. DNA Vaccines

    Article • January 2004, Springer Science + Business Media

    Dr Howard L Kaufman, howard kaufman

  68. The role of poxviruses in tumor immunotherapy

    Article • Surgery, November 2003, Elsevier

    Dr Howard L Kaufman, howard kaufman

  69. Chemokines and Cancer

    Article • Cancer Investigation, January 2002, Taylor & Francis

    howard kaufman

  70. Small bowel obstruction by jejunal enterolith

    Article • Surgery, February 1997, Elsevier

    howard kaufman

  71. Leiomyoma of the breast

    Article • Journal of Surgical Oncology, May 1996, Wiley

    howard kaufman

  72. Combination Cytokine Therapy

    Article • Springer Science + Business Media

    howard kaufman

  73. High Dose Interleukin-2 Therapy

    Article • Springer Science + Business Media

    howard kaufman

  74. Vaccines as Targeted Cancer Therapy

    Article • Springer Science + Business Media

    howard kaufman